{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T19:50:12Z","timestamp":1769197812038,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The hyper-activation of the Hippo\/YAP axis was observed in triple-negative breast cancer (TNBC), which was crucial for tumor progression. The over-activation of YAP in TNBC remains unexplained, despite the continued functionality of the inhibitory phospho-cascade. Recently, studies revealed that the ubiquitin modifications of YAP also play important roles in the Hippo\/YAP axis and cancer progression. In order to understand the potential mechanisms of ubiquitination and deubiquitination process in YAP function, we carried out siRNA screening for critical deubiquitinases in TNBC. Via the deubiquitinases (DUB) library, we identified Ubiquitin Specific Peptidase 8 (USP8) as an important effector in YAP function and TNBC progression. Inhibition of USP8 hampered TNBC progression via Hippo signaling. Clinical data revealed that USP8 expression correlated with YAP protein level and poor survival in TNBC patients. Biochemical evaluations revealed that USP8 has the ability to connect with YAP and suppress K48-linked polyubiquitination, thereby enhancing the stability of YAP. Interestingly, YAP directly binds to the USP8 promoter region, enhancing its transcription in TNBC. Our study revealed a forward feedback loop between USP8 and Hippo signaling in TNBC, indicating USP8 as a potential therapeutic drug targets in TNBC.<\/jats:p>","DOI":"10.1038\/s41419-025-08356-8","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T21:15:06Z","timestamp":1769030106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Positive feedback regulation between USP8 and Hippo\/YAP axis drives triple-negative breast cancer progression"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3315-3408","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penghe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianshi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7000-0474","authenticated-orcid":false,"given":"Peng","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenmiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen","family":"Fangyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3596-4339","authenticated-orcid":false,"given":"Jian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0862-1306","authenticated-orcid":false,"given":"Xiaodong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6308-1253","authenticated-orcid":false,"given":"Ting","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"8356_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938\u201348.","journal-title":"N Engl J Med"},{"key":"8356_CR2","doi-asserted-by":"publisher","first-page":"e4614","DOI":"10.1097\/MD.0000000000004614","volume":"95","author":"ML Plasilova","year":"2016","unstructured":"Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database. Medicine. 2016;95:e4614.","journal-title":"Medicine"},{"key":"8356_CR3","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1016\/j.ejca.2008.09.034","volume":"44","author":"JrWJ Irvin","year":"2008","unstructured":"Irvin JrWJ, Carey LA. What is triple-negative breast cancer? Eur J Cancer. 2008;44:2799\u2013805.","journal-title":"Eur J Cancer"},{"key":"8356_CR4","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1111\/bph.13211","volume":"172","author":"VS Jamdade","year":"2015","unstructured":"Jamdade VS, Sethi N, Mundhe NA, Kumar P, Lahkar M, Sinha N. Therapeutic targets of triple-negative breast cancer: a review. Br J Pharmacol. 2015;172:4228\u201337.","journal-title":"Br J Pharmacol"},{"key":"8356_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/carcin\/bgw077","volume":"37","author":"J Zhang","year":"2016","unstructured":"Zhang J, Yao S, Hu Q, Zhu Q, Liu S, Lunetta KL, et al. Genetic variations in the Hippo signaling pathway and breast cancer risk in African American women in the AMBER consortium. Carcinogenesis. 2016;37:951\u20136.","journal-title":"Carcinogenesis"},{"key":"8356_CR6","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/onc.2013.82","volume":"33","author":"W Bossuyt","year":"2014","unstructured":"Bossuyt W, Chen C-L, Chen Q, Sudol M, McNeill H, Pan D, et al. An evolutionary shift in the regulation of the Hippo pathway between mice and flies. Oncogene. 2014;33:1218\u201328.","journal-title":"Oncogene"},{"key":"8356_CR7","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1152\/physrev.00015.2021","volume":"102","author":"AM Chibly","year":"2022","unstructured":"Chibly AM, Aure MH, Patel VN, Hoffman MP. Salivary gland function, development, and regeneration. Physiol Rev. 2022;102:1495\u2013552.","journal-title":"Physiol Rev"},{"key":"8356_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.111745","volume":"387","author":"S Li","year":"2020","unstructured":"Li S, Li Q, Zhu Y, Hu W. GDF15 induced by compressive force contributes to osteoclast differentiation in human periodontal ligament cells. Exp Cell Res. 2020;387:111745.","journal-title":"Exp Cell Res"},{"key":"8356_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00018-014-1742-9","volume":"72","author":"M Kodaka","year":"2015","unstructured":"Kodaka M, Hata Y. The mammalian Hippo pathway: regulation and function of YAP1 and TAZ. Cell Mol Life Sci. 2015;72:285\u2013306.","journal-title":"Cell Mol Life Sci"},{"key":"8356_CR10","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1152\/physrev.00005.2014","volume":"94","author":"S Piccolo","year":"2014","unstructured":"Piccolo S, Dupont S, Cordenonsi M. The biology of YAP\/TAZ: Hippo signaling and beyond. Physiol Rev. 2014;94:1287\u2013312.","journal-title":"Physiol Rev"},{"key":"8356_CR11","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.73075","volume":"11","author":"FM Piccolo","year":"2022","unstructured":"Piccolo FM, Kastan NR, Haremaki T, Tian Q, Laundos TL, De Santis R, et al. Role of YAP in early ectodermal specification and a Huntington\u2019s disease model of human neurulation. Elife. 2022;11:e73075.","journal-title":"Elife"},{"key":"8356_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.critrevonc.2015.12.004","volume":"99","author":"M Maugeri-Sacc\u00e0","year":"2016","unstructured":"Maugeri-Sacc\u00e0 M, De Maria R. Hippo pathway and breast cancer stem cells. Crit Rev Oncol Hematol. 2016;99:115\u201322.","journal-title":"Crit Rev Oncol Hematol"},{"key":"8356_CR13","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s13277-014-2735-x","volume":"36","author":"H min Kim","year":"2015","unstructured":"min Kim H, Kim SK, Jung WH, Koo JS. Metaplastic carcinoma show different expression pattern of YAP compared to triple-negative breast cancer. Tumor Biol. 2015;36:1207\u201312.","journal-title":"Tumor Biol"},{"key":"8356_CR14","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1159\/000492520","volume":"48","author":"H Song","year":"2018","unstructured":"Song H, Wu T, Xie D, Li D, Hua K, Hu J, et al. WBP2 downregulation inhibits proliferation by blocking YAP transcription and the EGFR\/PI3K\/Akt signaling pathway in triple negative breast cancer. Cell Physiol Biochem. 2018;48:1968\u201382.","journal-title":"Cell Physiol Biochem"},{"key":"8356_CR15","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/cancers14061480","volume":"14","author":"L Casalino","year":"2022","unstructured":"Casalino L, Talotta F, Cimmino A, Verde P. The Fra-1\/AP-1 oncoprotein: from the \u201cundruggable\u201d transcription factor to therapeutic targeting. Cancers. 2022;14:1480.","journal-title":"Cancers"},{"key":"8356_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/ncb2756","volume":"15","author":"F Calvo","year":"2013","unstructured":"Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013;15:637\u201346.","journal-title":"Nat Cell Biol"},{"key":"8356_CR17","first-page":"1611","volume":"128","author":"J Luo","year":"2023","unstructured":"Luo J, Zou H, Guo Y, Tong T, Chen Y, Xiao Y, et al. The oncogenic roles and clinical implications of YAP\/TAZ in breast cancer. Br J Cancer. 2023;128:1611\u201324.","journal-title":"Br J Cancer"},{"key":"8356_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.canlet.2021.02.003","volume":"504","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Fan Y, Jing X, Zhao L, Liu T, Wang L, et al. OTUD5-mediated deubiquitination of YAP in macrophage promotes M2 phenotype polarization and favors triple-negative breast cancer progression. Cancer Lett. 2021;504:104\u201315.","journal-title":"Cancer Lett"},{"key":"8356_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bbcan.2015.06.005","volume":"1856","author":"X Zou","year":"2015","unstructured":"Zou X, Levy-Cohen G, Blank M. Molecular functions of NEDD4 E3 ubiquitin ligases in cancer. Biochim Biophys Acta Rev Cancer. 2015;1856:91\u2013106.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8356_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd.2017.152","volume":"17","author":"JA Harrigan","year":"2018","unstructured":"Harrigan JA, Jacq X, Martin NM, Jackson SP. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018;17:57\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"8356_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.molcel.2021.10.027","volume":"82","author":"SM Lange","year":"2022","unstructured":"Lange SM, Armstrong LA, Kulathu Y. Deubiquitinases: from mechanisms to their inhibition by small molecules. Mol Cell. 2022;82:15\u201329.","journal-title":"Mol Cell"},{"key":"8356_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29401-6","volume":"13","author":"W Xiong","year":"2022","unstructured":"Xiong W, Gao X, Zhang T, Jiang B, Hu M-M, Bu X, et al. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nat Commun. 2022;13:1700.","journal-title":"Nat Commun"},{"key":"8356_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302953","volume":"10","author":"J Tang","year":"2023","unstructured":"Tang J, Long G, Hu K, Xiao D, Liu S, Xiao L, et al. Targeting USP8 inhibits O-GlcNAcylation of SLC7A11 to promote ferroptosis of hepatocellular carcinoma via stabilization of OGT. Adv Sci. 2023;10:2302953.","journal-title":"Adv Sci"},{"key":"8356_CR24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.molcel.2019.06.010","volume":"75","author":"C Zhu","year":"2019","unstructured":"Zhu C, Li L, Zhang Z, Bi M, Wang H, Su W, et al. A non-canonical role of YAP\/TEAD is required for activation of estrogen-regulated enhancers in breast cancer. Mol Cell. 2019;75:791\u2013806.","journal-title":"Mol Cell"},{"key":"8356_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"key":"8356_CR26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1158\/0008-5472.CAN-22-2709","volume":"83","author":"L Liao","year":"2023","unstructured":"Liao L, Zhang Y-L, Deng L, Chen C, Ma X-Y, Andriani L, et al. Protein phosphatase 1 subunit PPP1R14B stabilizes STMN1 to promote progression and paclitaxel resistance in triple-negative breast cancer. Cancer Res. 2023;83:471\u201384.","journal-title":"Cancer Res"},{"key":"8356_CR27","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cells8090957","volume":"8","author":"M Nedeljkovi\u0107","year":"2019","unstructured":"Nedeljkovi\u0107 M, Damjanovi\u0107 A. Mechanisms of chemotherapy resistance in triple-negative breast cancer\u2014how we can rise to the challenge. Cells. 2019;8:957.","journal-title":"Cells"},{"key":"8356_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.biochi.2007.09.013","volume":"90","author":"L Daviet","year":"2008","unstructured":"Daviet L, Colland F. Targeting ubiquitin specific proteases for drug discovery. Biochimie. 2008;90:270\u201383.","journal-title":"Biochimie"},{"key":"8356_CR29","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108791","volume":"41","author":"F Xie","year":"2022","unstructured":"Xie F, Zhou X, Li H, Su P, Liu S, Li R, et al. USP8 promotes cancer progression and extracellular vesicle-mediated CD8+ T cell exhaustion by deubiquitinating the TGF-\u03b2 receptor T\u03b2RII. EMBO J. 2022;41:e108791.","journal-title":"EMBO J"},{"key":"8356_CR30","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/15548627.2015.1009794","volume":"11","author":"TM Durcan","year":"2015","unstructured":"Durcan TM, Fon EA. USP8 and PARK2\/parkin-mediated mitophagy. Autophagy. 2015;11:428\u20139.","journal-title":"Autophagy"},{"key":"8356_CR31","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.15252\/embj.201489729","volume":"33","author":"TM Durcan","year":"2014","unstructured":"Durcan TM, Tang MY, P\u00e9russe JR, Dashti EA, Aguileta MA, McLelland GL, et al. USP 8 regulates mitophagy by removing K 6-linked ubiquitin conjugates from parkin. EMBO J. 2014;33:2473\u201391.","journal-title":"EMBO J"},{"key":"8356_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.bbrc.2023.10.037","volume":"682","author":"D Jiao","year":"2023","unstructured":"Jiao D, Chen Y, Liu X, Tang X, Chen J, Liu Y, et al. Targeting MET endocytosis or degradation to overcome HGF-induced gefitinib resistance in EGFR-sensitive mutant lung adenocarcinoma. Biochem Biophys Res Commun. 2023;682:371\u201380.","journal-title":"Biochem Biophys Res Commun"},{"key":"8356_CR33","doi-asserted-by":"publisher","first-page":"14999","DOI":"10.18632\/aging.203061","volume":"13","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Xu J, Hu W, Wang F, Zhou Y, Gong W, et al. Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases. Aging. 2021;13:14999.","journal-title":"Aging"},{"key":"8356_CR34","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","volume":"5","author":"EA Chapeau","year":"2024","unstructured":"Chapeau EA, Sansregret L, Galli GG, Ch\u00e8ne P, Wartmann M, Mourikis TP, et al. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers. Nat Cancer. 2024;5:1102\u201320.","journal-title":"Nat Cancer"},{"key":"8356_CR35","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.7150\/thno.40889","volume":"10","author":"AV Pobbati","year":"2020","unstructured":"Pobbati AV, Hong W. A combat with the YAP\/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020;10:3622.","journal-title":"Theranostics"},{"key":"8356_CR36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/cancers13020318","volume":"13","author":"R Zeng","year":"2021","unstructured":"Zeng R, Dong J. The Hippo signaling pathway in drug resistance in cancer. Cancers. 2021;13:318.","journal-title":"Cancers"},{"key":"8356_CR37","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","volume":"19","author":"A Dey","year":"2020","unstructured":"Dey A, Varelas X, Guan K-L. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020;19:480\u201394.","journal-title":"Nat Rev Drug Discov"},{"key":"8356_CR38","doi-asserted-by":"crossref","unstructured":"Yang NJ, Hinner MJ. Getting across the cell membrane: an overview for small molecules, peptides, and proteins. Site-specific protein labeling. Methods and protocols. 2015;1266:29\u201353.","DOI":"10.1007\/978-1-4939-2272-7_3"},{"key":"8356_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev.biophys.33.110502.133337","volume":"34","author":"W Cho","year":"2005","unstructured":"Cho W, Stahelin RV. Membrane-protein interactions in cell signaling and membrane trafficking. Annu Rev Biophys Biomol Struct. 2005;34:119\u201351.","journal-title":"Annu Rev Biophys Biomol Struct"},{"key":"8356_CR40","doi-asserted-by":"publisher","first-page":"9443","DOI":"10.7150\/thno.46078","volume":"10","author":"X Zhou","year":"2020","unstructured":"Zhou X, Li Y, Wang W, Wang S, Hou J, Zhang A, et al. Regulation of Hippo\/YAP signaling and esophageal squamous carcinoma progression by an E3 ubiquitin ligase PARK2. Theranostics. 2020;10:9443.","journal-title":"Theranostics"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08356-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08356-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08356-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T15:17:49Z","timestamp":1769181469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08356-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8356"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08356-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was reviewed and approved by the Ethical Board at Xinxiang Medical University (XYLL-20240394). All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"98"}}